Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Dental devices market to rebound in 2021 as acquisitions rise

The COVID-19 pandemic saw certain markets such as anesthesia and respirator devices grow in 2020, while many others such as dental devices stagnated or saw a huge decline. However, dental devices are projected to make a strong recovery in 2021. The global market value for dental devices in 2021 is estimated to be $20.5bn, up […]
Read more

Interim data from UK study ‘Com-COV’ suggest higher reactogenicity

Preliminary safety results from the Oxford led Phase II Com-COV trial investigating immune responses in patients given heterologous prime-boost vaccine schedules indicate that mixing vaccines leads to higher reactogenicity and more frequent side effects, observes GlobaData, a leading data and analytics company. Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData, comments: “The preliminary safety results may […]
Read more

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs in head-to-head clinical trials, says GlobalData

Eli Lilly’s highly anticipated tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide has the potential […]
Read more

COVID-19 puts Cadila Healthcare at the forefront of innovation in India, says GlobalData

Cadila Healthcare Ltd. is among the leading players in India which focuses on bringing in-house developed innovative therapies for patients. Cadila Healthcare has developed a diversified COVID-19 portfolio among the Indian players through in-house development and licensing opportunities. In line with this, the COVID-19 pandemic has put Cadila Healthcare at the forefront of innovation in […]
Read more

Bristol-Myers Squibb’s Mavacamten demonstrates significant improvement of health status for symptomatic oHCM patients in the EXPLORER-HCM trial, says GlobalData

At the 70th annual American College of Cardiology (ACC) 2021 meeting, positive data from the EXPLORE-HCM trial was presented for Bristol-Myers Squibb’s mavacamten, a targeted inhibitor of cardiac-myosin that is currently at the pre-registration stage of development in the US for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). According to GlobalData, a leading data […]
Read more

High unmet needs in HNSCC may be partially addressed by clinical development over next decade, says GlobalData

Improved efficacy for HNSCC therapeutics able to demonstrate an overall survival benefit remains a key unmet need in the indication. The next decade may see the introduction of personalized therapy options in locally advanced HNSCC settings along with identification of new druggable targets. Research is being conducted to test therapeutic de-intensification in oropharyngeal carcinoma patients. […]
Read more

Boehringer’s BI 425809 has potential to address cognitive impairment in schizophrenia market, says GlobalData

Boehringer Ingelheim recently announced that its product, BI 425809, has received Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for Cognitive Impairment Associated with Schizophrenia (CIAS). There are currently no approved pharmacological treatments for CIAS and if BI 425809 is successful, it could address this unmet need in the schizophrenia market. […]
Read more

Long-acting growth hormones to account for over 90% of growth hormone deficiency market share across US, Germany, and Japan by 2030, says GlobalData

Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany and Japan. These therapies are projected to capture over 90% of market share in this region by 2030 due to their potential to improve patient convenience and compliance, […]
Read more

ANVS401’s trial hints at promising new approach for early Parkinson’s treatment, says GlobalData

Annovis Bio recently announced positive results from a Phase IIa trial of its pipeline asset ANVS401 (posiphen) in patients with early Parkinson’s disease (PD). The data presented further strengthens the previous interim trial findings, where ANVS401 showed an improvement in the overall motor skill functions of PD patients with no serious adverse events, says GlobalData, […]
Read more

BCMA-targeting therapy market to become highly competitive in the next five years, says GlobalData

Therapies targeting B-cell maturation antigen (BCMA) now account for approximately 10% of immuno-oncology drugs in Phase I-III development globally. With just two marketed agents available targeting BCMA, and impressive clinical data emerging from pipeline agents, the market for BCMA-targeting therapies is set to become increasingly competitive in the near future, says GlobalData a leading data […]
Read more

World MS Day: Opportunities remain for products that fulfil significant unmet needs in the MS market, says GlobalData

The multiple sclerosis (MS) therapeutics market is becoming increasingly crowded, but the overall fulfillment of unmet needs is medium. There are no curative therapies for MS, and most existing disease modifying therapies (DMTs) are only partially effective in preventing relapses, with limited impact on the accrual of disability. This means that most patients still experience […]
Read more

Bio/Pharma industry works to solve worldwide shortage of viral vector component used in many COVID-19 vaccines

The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J), says GlobalData, a leading data and analytics company. GlobalData’s report, ‘The Outlook for Viral […]
Read more
,

Strategic reorganization, increased investment in antibody drug conjugates reaffirm Daiichi Sankyo’s long-term oncology goals, says GlobalData

Japanese pharmaceutical company Daiichi Sankyo received a major headway in the global oncology space with the launch of its first antibody drug conjugate (ADC) therapy trastuzumab (Enhertu). In addition to the strong ADC follow-up pipeline, the establishment of a new unified oncology business unit aligning the US and EU markets and increased investment in ADC […]
Read more
1 … 63 64 65 66 67 … 110